Representation matters: a call for inclusivity and equity in heart failure clinical trials

Nosheen Reza, Aditi Nayak, Sabra C. Lewsey, Ersilia M. DeFilippis

Research output: Contribution to journalArticlepeer-review


The burden of heart failure remains substantial worldwide, and heart failure with reduced ejection fraction (HFrEF) affects approximately half of this population. Despite this global prevalence of HFrEF, the majority of contemporary clinical trials in HFrEF have underenrolled individuals from minoritized sex, gender, race, ethnicity, and socioeconomic groups. Moreover, significant disparities in access to HFrEF treatment and outcomes exist across these same strata. We provide a call to action for the inclusion of diverse populations in HFrEF clinical trials; catalogue several barriers to adequate representation in HFrEF clinical trials; and propose strategies to broaden inclusivity in future HFrEF trials.

Original languageEnglish (US)
Pages (from-to)L45-L48
JournalEuropean Heart Journal, Supplement
Issue numberSl
StatePublished - Dec 1 2022


  • Clinical trials
  • Diversity
  • Health equity
  • Heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Representation matters: a call for inclusivity and equity in heart failure clinical trials'. Together they form a unique fingerprint.

Cite this